Research
/
Stock
/
VRTX
V
VRTX
VERTEX PHARMACEUTICALS INC / MA
FY2025
i
Mkt cap 140.4B
552.85
+5.26 +0.96%
close 2026-08-25
i
Overview
Financials
Insider
DCF
Research
/
Stock
/
…
Pulling SEC filings & building this page… the first lookup of a new ticker takes a few seconds, then it's cached.
Mkt Cap
i
140.4B
P/E
i
36.1
Revenue FY2025
i
12.0B
Gross Margin
i
86.2%
FCF FY2025
i
3.2B
Net Income
i
4.0B
52-week range
i
376.62
at its high
i
552.85
Beta
i
0.57
vs S&P 500 · 1254 common days
Dividend
i
—
no dividend line in the cash flow statement
Price
i
1M
6M
1Y
5Y
i
i
Revenue
i
12.0B
FY2025
i
·
+8.9% YoY
i
i
EBITDA
i
4.4B
FY2025 · operating + D&A
Free Cash Flow
i
3.2B
FY2025
i
·
+504.1% YoY
i
i
EPS (diluted)
i
15.32
FY2025
i
·
+836.5% YoY
i
i
Earnings
i
next est.
Last reported
3 Aug 2026 · 8-K (2.02)
Next report
≈ 2 Nov 2026
Moat & Risks
i
Engine pending
86.2% gross margin (FY2025) — pricing-power signal.
FY2025 10-K ›
Revenue +8.90% YoY to 12.0B (FY2025).
FY2025 10-K ›
Sourced moat / risk brief — generated by the Silkcodex engine (pending run).
Insider activity
i
Section 16
i
All transactions →
No Form 4 filings on file. Most foreign private issuers are exempt from Section 16, and coverage of the rest is a capped recent window — an empty panel is not evidence of no insider activity.
Recent filings
SEC EDGAR
i
No filings on file.